Azaindazole compounds as CCR1 receptor antagonists

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of...

Full description

Saved in:
Bibliographic Details
Main Authors THOMAS WAI-HO LEE, BRIAN CHRISTOPHER RAUDENBUSH, HOSSEIN RAZAVI, JINHUA J. SONG, DARREN DISALVO, ZHULIN TAN, PINGRONG LIU, JONATHAN TIMOTHY REEVES, ALAN DAVID SWINAMER, DANIEL ROBERT FANDRICK, CAN MAO, JOHN LORD, CHRISTIAN HARCKEN, BRIAN NICHOLAS COOK, DANIEL KUZMICH, JOCHEN NEU
Format Patent
LanguageEnglish
Published 01.04.2010
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
Bibliography:Application Number: AU20090296839